Cited by 1,086SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesRespiratory viral infections research

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Open access

Gupta, Anil, Gonzalez-Rojas, Yaneicy, Juarez, Erick, Crespo Casal, Manuel, Moya, Jaynier, Falci, Diego R., Sarkis, Elias, Solis, Joel, Zheng, Hanzhe, Scott, Nicola, Cathcart, Andrea L., Hebner, Christy M., Sager, Jennifer, Mogalian, Erik, Tipple, Craig, Peppercorn, Amanda, Alexander, Elizabeth, Pang, Phillip S., Free, Almena, Brinson, Cynthia, Aldinger, Melissa, Shapiro, Adrienne E.·2021·New England Journal of Medicine

DOI 10.1056/nejmoa2107934

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization or death in older patients and those with underlying conditions. Sotrovimab is a pan-sarbecovirus monoclonal antibody that was designed to prevent progression of Covid-19 in high-risk patients early in the course of disease. METHODS: In this ongoing, multicenter, double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, nonhospitalized patients with symptomatic Covid-19 (≤5 days after the onset of symptoms) and at least one risk factor for disease progression to receive a single infusion of sotrovimab at a dose of 500 mg or placebo. The primary efficacy outcome was hospitalization (for >24 hours) for any cause or death within 29 days after randomization. RESULTS: In this prespecified interim analysis, which included an intention-to-treat population of 583 patients (291 in the sotrovimab group and 292 in the placebo group), 3 patients (1%) in the sotrovimab group, as compared with 21 patients (7%) in the placebo group, had disease progression leading to hospitalization or death (relative risk reduction, 85%; 97.24% confidence interval, 44 to 96; P = 0.002). In the placebo group, 5 patients were admitted to the intensive care unit, including 1 who died by day 29. Safety was assessed in 868 patients (430 in the sotrovimab group and 438 in the placebo group). Adverse events were reported by 17% of the patients in the sotrovimab group and 19% of those in the placebo group; serious adverse events were less common with sotrovimab than with placebo (in 2% and 6% of the patients, respectively). CONCLUSIONS: Among high-risk patients with mild-to-moderate Covid-19, sotrovimab reduced the risk of disease progression. No safety signals were identified. (Funded by Vir Biotechnology and GlaxoSmithKline; COMET-ICE ClinicalTrials.gov number, NCT04545060.).

Integrity signals

Registry

Crossref · 10.1056/nejmoa2107934

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study
Petrilli, C. M., Jones, S. A., Yang, J., Rajagopalan, H., O’Donnell, L., Chernyak, Y., Tobin, K. A., Cerfolio, R. J., François, F., & Horwitz, L. I. (2020) · BMJ · doi:10.1136/bmj.m1966 · Cited by 3,045
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312
Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020
CDC COVID-19 Response Team, CDC COVID-19 Response Team, Bialek, S. R., Boundy, E. O., Bowen, V. B., Chow, N. A., Cohn, A. C., Dowling, N. F., Ellington, S., Gierke, R., et al. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6912e2 · Cited by 2,278
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
Weinreich, D. M., Sivapalasingam, S., Norton, T., Ali, S., Gao, H., Bhore, R., Musser, B. J., Soo, Y., Rofail, D., Im, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035002 · Cited by 1,642
Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19
Liang, W., Liang, H., Ou, L., Chen, B., Chen, A., Li, C., Li, Y., Guan, W., Sang, L., Lu, J., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.2033 · Cited by 1,387
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Chen, P., Nirula, A., Heller, B., Gottlieb, R. L., Boscia, J., Morris, J., Huhn, G., Cardona, J., Mocherla, B., Stosor, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029849 · Cited by 1,282
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
Chen, R. E., Zhang, X., Case, J. B., Winkler, E. S., Liu, Y., VanBlargan, L. A., Liu, J., Errico, J. M., Xie, X., Suryadevara, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01294-w · Cited by 881

Flagged first, then by citations

Show all 25 references

Sorted by citations

Items 501–600 of 1,000

Monoclonal Antibodies as Long-Acting Products: What Are We Learning From Human Immunodeficiency Virus (HIV) and Coronavirus Disease 2019 (COVID-19)?
Caskey, M. F., & Kuritzkes, D. R. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac751 · Cited by 8
COVID-19 in Patients with Hematologic Diseases
Casetti, I. C., Borsani, O., & Rumi, E. (2022) · Biomedicines · doi:10.3390/biomedicines10123069 · Cited by 8
Real‐world effectiveness of sotrovimab and remdesivir for early treatment of high‐risk hospitalized COVID‐19 patients: A propensity score adjusted retrospective cohort study
Koh, L. P., Chua, S. L., Vasoo, S. S., Toh, M. P. H. S., Cutter, J. N., Nah, P. H., Leo, Y., Tay, J. X., Young, B. E., Lye, D. C., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28460 · Cited by 7
Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO)
Tuan, J., Sharma, M., Kayani, J., Davis, M. W., McManus, D. S., Topal, J. E., & Ogbuagu, O. E. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08198-9 · Cited by 7
COVID-19: Variants, Immunity, and Therapeutics for Non-Hospitalized Patients
Lee, C. Y. S., & Suzuki, J. B. (2023) · Biomedicines · doi:10.3390/biomedicines11072055 · Cited by 7
Does monoclonal antibody treatment for COVID-19 impact short and long-term outcomes in a large generalisable population? A retrospective cohort study in the USA
Griffin, D. O., McNeil, C., Okusa, J., Berrent, D., Guo, Y., & Daugherty, S. E. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-069247 · Cited by 7
Modulation of various host cellular machinery during COVID‐19 infection
Malvankar, S., Singh, A., Kumar, Y., Sahu, S., Shah, M., Murghai, Y., Seervi, M., Srivastava, R. K., & Verma, B. (2023) · Reviews in Medical Virology · doi:10.1002/rmv.2481 · Cited by 7
An Update on SARS-CoV-2 Clinical Trial Results—What We Can Learn for the Next Pandemic
Arman, B. Y., Brun, J., Hill, M. L., Zitzmann, N., & von Delft, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010354 · Cited by 8
Emerging anti-spike monoclonal antibodies against SARS-CoV-2
Ordaya, E. E., & Razonable, R. R. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2326647 · Cited by 7
Community-Acquired Pneumonia in Canada During Coronavirus Disease 2019
Mandell, L. A., Zhanel, G. G., Rotstein, C., Muscedere, J., Loeb, M. B., & Johnstone, J. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac043 · Cited by 7
The Differentiation and Maintenance of SARS-CoV-2-Specific Follicular Helper T Cells
Wang, Y., Qin, T., & Ye, L. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.953022 · Cited by 7
COVID-19 symptom-onset to diagnosis and diagnosis to treatment intervals are significant predictors of disease progression and hospitalization in high-risk patients: A real world analysis
Shimizu, H., Kawase, J., Hayashi, M., Imaizumi, K., Ito, Y., & Okazawa, M. (2023) · Respiratory Investigation · doi:10.1016/j.resinv.2023.01.002 · Cited by 7
Combination of spironolactone and sitagliptin improves clinical outcomes of outpatients with COVID-19: a prospective cohort study
Davarpanah, M. A., Adatorwovor, R., Mansoori, Y., Ramsheh, F. S. R., Parsa, A., Hajiani, M., Faramarzi, H., Kavuluru, R., & Asadipooya, K. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02141-0 · Cited by 7
Immune-based therapeutic approaches in COVID-19
Moeinafshar, A., Yazdanpanah, N., & Rezaei, N. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113107 · Cited by 7
Monoclonal Antibodies with Extended Half-Life to Prevent Covid-19
Abraham, J. (2022) · New England Journal of Medicine · doi:10.1056/nejme2205563 · Cited by 7
Relationship between the inclusion/exclusion criteria and sample size in randomized controlled trials for SARS-CoV-2 entry inhibitors
Tatematsu, D., Akao, M., Park, H., Iwami, S., Ejima, K., & Iwanami, S. (2022) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2022.111403 · Cited by 6
A Model-Based Cost-Effectiveness Analysis of Long-Acting Monoclonal Antibody (Tixagevimab and Cilgavimab: Evusheld) Preventive Treatment for High-Risk Populations Against SARS-CoV-2 in Korea
Jo, Y., Kim, S. B., & Jung, J. (2023) · Journal of Korean Medical Science · doi:10.3346/jkms.2023.38.e250 · Cited by 6
Dendritic Cell‐Mediated Cross‐Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS‐CoV‐2
Lázaro‐Gorines, R., Pérez, P., Heras‐Murillo, I., Adán‐Barrientos, I., Albericio, G., Astorgano, D., Flores, S., Luczkowiak, J., Labiod, N., Harwood, S. L., et al. (2023) · Advanced Science · doi:10.1002/advs.202304818 · Cited by 6
A comprehensive review on immunogen and immune-response proteins of SARS-CoV-2 and their applications in prevention, diagnosis, and treatment of COVID-19
Zhang, D., Kukkar, D., Kim, K., & Bhatt, P. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.129284 · Cited by 6
Pulmonary Pharmacokinetics of Antibody and Antibody Fragments Following Systemic and Local Administration in Mice
Jagdale, P., Verma, A., & Shah, D. K. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16101259 · Cited by 6
Severe outcomes of COVID-19 among adults with increased risk conditions: A population-based observational study
Dryden‐Peterson, S., Kim, A., Caniglia, E. C., Joyce, M.-R. M., Rubins, D. M., Kim, A. Y., Fangman, J. J. W., Baden, L. R., & Woolley, A. E. (2025) · PLoS ONE · doi:10.1371/journal.pone.0316529 · Cited by 8
Engineered DPP4 decoy confers broad-spectrum inhibition of MERS-CoV infection
Nishioka, K., Sakai, Y., Motooka, D., Iwata‐Yoshikawa, N., Tojo, H., Matoba, S., Nagata, N., Nakaya, T., Arimori, T., & Hoshino, A. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100018 · Cited by 6
An integrated multiscale computational framework deciphers SARS-CoV-2 resistance to sotrovimab
Sharma, A., Maurya, S., Kumar, S., Tripathi, T., Kar, R. K., & Padhi, A. K. (2025) · Biophysical Journal · doi:10.1016/j.bpj.2025.05.015 · Cited by 6
Immune Evasion by the Highly Mutated SARS-CoV-2 Omicron Variant
Mengist, H. M., Kombe, A. J. K., & Jin, T. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s366437 · Cited by 6
Immune-related adverse events of biological immunotherapies used in COVID-19
Baracaldo-Santamaría, D., Barros-Arias, G. M., Hernández-Guerrero, F., de‐la‐Torre, A., & Calderón‐Ospina, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.973246 · Cited by 6
Monoclonal antibody treatment of COVID-19 in a pregnant woman with common variable immunodeficiency
Aberumand, B., Kamal, R., McKinney, B. J., & Betschel, S. (2022) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-022-00730-x · Cited by 6
Inhibition of coronavirus HCoV-OC43 by targeting the eIF4F complex
Feng, Y., Grotegut, S., Jovanović, P., Gandin, V., Olson, S. H., Murad, R., Beall, A. E., Colayco, S., DeJesus, P., Chanda, S. K., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1029093 · Cited by 6
Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS‐CoV ‐2 neutralizing monoclonal antibody ABBV‐47D11 in patients with COVID ‐19
Shebley, M., Wang, S., Ali, I., Krishnan, P., Tripathi, R. L., Reardon, J. M., Cafardi, J. M., Rahav, G., Caraco, Y., Slim, J., et al. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1036 · Cited by 6
Regdanvimab for patients with mild-to-moderate COVID-19: a retrospective cohort study and subgroup analysis of patients with the Delta variant
Jang, Y. R., Oh, Y. J., & Kim, J. Y. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.12.035 · Cited by 8
COVID-19-Associated Myocardial Injury: A Case Report
Tadokoro, T., Ohta‐Ogo, K., Ikeda, Y., Sugiyama, M., Katano, H., Hatakeyama, K., Matsumoto, M., & Tashiro, H. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14295 · Cited by 6
VDDB: A comprehensive resource and machine learning tool for antiviral drug discovery
Tao, S., Chen, Y., Wu, J., Zhao, D., Cai, H., & Wang, L. (2023) · MedComm – Future Medicine · doi:10.1002/mef2.32 · Cited by 6
Use of Sotrovimab in a cohort of pregnant women with a high risk of COVID 19 progression: a single-center experience
Frallonardo, L., Vimercati, A., Novara, R., Lepera, C., Ferrante, I., Chiarello, G., Cicinelli, R., Mongelli, M., Brindicci, G., Segala, F. V., et al. (2023) · Pathogens and Global Health · doi:10.1080/20477724.2023.2188839 · Cited by 6
An Enhanced Dissolving Cyclosporin-A Inhalable Powder Efficiently Reduces SARS-CoV-2 Infection In Vitro
D’Angelo, D., Quarta, E., Glieca, S., Varacca, G., Flammini, L., Bertoni, S., Brandolini, M., Sambri, V., Grumiro, L., Gatti, G., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15031023 · Cited by 6
Effectiveness of Sotrovimab in Preventing COVID-19-Related Hospitalizations or Deaths Among US Veterans During Omicron BA.1
Young‐Xu, Y., Korves, C., Zwain, G., Satram, S., Drysdale, M., Reyes, C. M., Cheng, M. M., Bonomo, R. A., Epstein, L. H., Marconi, V. C., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad605 · Cited by 6
Drug discovery to treat COVID-19 two years after its outbreak
Gao, J., & Sun, F. (2021) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2021.01302 · Cited by 6
Current challenges in different approaches to control COVID-19: a comprehensive review
Giri, S., Sen, S., Singh, R., Paul, P., Sahu, R., Nandi, G., & Dua, T. K. (2022) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-022-00730-2 · Cited by 6
Characteristics and Outcomes of Ambulatory Patients with Suspected COVID-19 at a Respiratory Referral Center
Guntur, V. P., Modena, B. D., Manka, L. A., Eddy, J. J., Liao, S., Goldstein, N. M., Zelarney, P. T., Horn, C. A., Keith, R. C., Make, B. J., et al. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2022.106832 · Cited by 6
Benefit of monoclonal antibodies in early treatment of COVID-19 after lung transplantation: a retrospective analysis in two centres
Gottlieb, J., Kolditz, M., Gade, N., Welte, T., & Kneidinger, N. (2022) · European Respiratory Journal · doi:10.1183/13993003.00124-2022 · Cited by 6
The burden of SARS-CoV-2 in patients receiving chimeric antigen receptor T cell immunotherapy: everything to lose
Paz, D. L., Sesques, P., Wallet, F., Bachy, E., & Ader, F. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2022.2101448 · Cited by 6
Effect of fluvoxamine on outcomes of nonhospitalized patients with COVID-19: A systematic review and meta-analysis
Lu, L., Chao, C., Chang, S.-P., Lan, S., & Lai, C. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.10.010 · Cited by 6
Mortality and risk factors of vaccinated and unvaccinated frail patients with COVID-19 treated with anti-SARS-CoV-2 monoclonal antibodies: A real-world study
Nevola, R., Feola, G., Ruocco, R., Russo, A., Villani, A., Fusco, R., Pascalis, S. D., Core, M. D., Cirigliano, G., Pisaturo, M., et al. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.03.030 · Cited by 6
Drug interventions for prevention of COVID-19 progression to severe disease in outpatients: a systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Petersen, J. J., Kamp, C. B., Faltermeier, P., Siddiqui, F., Feinberg, J. B., Nielsen, E. E., Kristensen, A. T., Juul, S., Holgersson, J., Nielsen, N., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-064498 · Cited by 6
Current Strategies in Treating Cytokine Release Syndrome Triggered by Coronavirus SARS-CoV-2
Wang, L. G., & Wang, L. (2022) · ImmunoTargets and Therapy · doi:10.2147/itt.s360151 · Cited by 6
A review of clinical efficacy data supporting emergency use authorization for COVID ‐19 therapeutics and lessons for future pandemics
Yoo, S., Kim, L., Lu, M. M., Nagoshi, K., & Namchuk, M. (2022) · Clinical and Translational Science · doi:10.1111/cts.13384 · Cited by 6
Antiviral T-cell Biofactory platform for SARS-CoV-2Preprint
Ssemadaali, M. A., Newmyer, S. L., Radhakrishnan, H., Arredondo, J., Javitz, H. S., Dandekar, S., & Bhatnagar, P. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.26.497669 · Cited by 6
Dry loop–mediated isothermal amplification assay for detection of SARS-CoV-2 from clinical specimensPreprint
Higashimoto, Y., Ihira, M., Kawamura, Y., Inaba, M., Shirato, K., Suzuki, T., Hasegawa, H., Kageyama, T., Doi, Y., Hata, T., et al. (2020) · medRxiv · doi:10.1101/2020.09.29.20204297 · Cited by 6
Sotrovimab: is it effective in early treatment of mild and moderate COVID-19 infections? A retrospective study
Elesdoudy, A. A. (2021) · Egyptian Journal of Bronchology · doi:10.1186/s43168-021-00104-8 · Cited by 5
Current therapies for chronic lymphocytic leukemia: risk and prophylaxis strategies for secondary/opportunistic infections
Diella, L., Bavaro, D. F., Loseto, G., Pasciolla, C., Minoia, C., Gennaro, D. D., Belati, A., Candia, M. S. D., Gennaro, F. D., Saracino, A., et al. (2023) · Expert Review of Hematology · doi:10.1080/17474086.2023.2192918 · Cited by 5
Impact of SARS-CoV-2 Resistance to Antiviral Monoclonal Antibody Therapy on Neutralizing Antibody Response
Paul, M.-K., Choudhary, M. C., Heaps, A., Deo, R., Moisi, D. D., Gordon, K. C., Mellors, J. W., Moser, C., Klekotka, P. A., LANDAY, A. L., et al. (2024) · Pathogens and Immunity · doi:10.20411/pai.v9i2.718 · Cited by 5
COVID ‐19 in pregnancy
Greer, O., Saeed, Z., Woon, E. V., Singh, N., Johnson, M., & Shah, N. M. (2025) · The Obstetrician & Gynaecologist · doi:10.1111/tog.12960 · Cited by 5
Development of the TSR-based computational method to investigate spike and monoclonal antibody interactions
Milon, T. I., Sarkar, T., Chen, Y., Grider, J. M., Chen, F., Ji, J., Jois, S. D. S., Kousoulas, K. G., Raghavan, V. V., & Xu, W. (2025) · Frontiers in Chemistry · doi:10.3389/fchem.2025.1395374 · Cited by 5
Monoclonal Antibodies for Pediatric Viral Disease Prevention and Treatment
Bahadir, Z., Narayan, P., Wolters, R. M., Permar, S. R., Fouda, G. G., Hessell, A. J., & Haigwood, N. L. (2025) · PEDIATRICS · doi:10.1542/peds.2024-068690 · Cited by 6
Recommendations for the outpatient drug treatment of patients with COVID-19
Kaduszkiewicz, H., Kochen, M. M., Kluge, S., Malin, J. J., Weibel, S., & Skoetz, N. (2022) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2022.0203 · Cited by 5
Current Therapeutics for COVID-19, What We Know about the Molecular Mechanism and Efficacy of Treatments for This Novel Virus
Narayanan, D., & Parimon, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147702 · Cited by 5
Improved Survival of Lymphoma Patients with COVID-19 in the Modern Treatment and Vaccination Era
Pia, A. D., Zhao, C., Jandir, P., Gupta, A., Batistick, M., Kim, G. Y., Xia, Y., Ahn, J., Magarelli, G., Lukasik, B., et al. (2022) · Cancers · doi:10.3390/cancers14174252 · Cited by 5
Self-citation
Predictors of Coronavirus Disease 2019 Hospitalization After Sotrovimab in Patients With Hematologic Malignancy During the BA.1 Omicron Surge
Yan, J., Steiger, S. N., Kodama, R., Fender, J., Tan, C. A., Laracy, J. C., Cohen, N., McMillen, T. A., Jani, K., Robilotti, E. V., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac916 · Cited by 5
Aloin A inhibits SARS CoV-2 replication by targeting its binding with ACE2 - Evidence from modeling-supported molecular dynamics simulation
Alhadrami, H. A., Sayed, A. M., Hassan, H. M., & Rateb, M. E. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2175262 · Cited by 5
COVID-19 in solid organ transplant recipients after 2 years of pandemic: Outcome and impact of antiviral treatments in a single-center study
Pinchera, B., Buonomo, A. R., Trucillo, E., Susini, S. M., D’Agostino, A., Filippo, I. D., Tanzillo, A., Villari, R., Carrano, R., Troisi, R. I., et al. (2023) · Frontiers in Transplantation · doi:10.3389/frtra.2023.1095225 · Cited by 5
Severe COVID-19: Drugs and Clinical Trials
Ceja-Gálvez, H. R., Renteria-Flores, F. I., Nicoletti, F., Hernández‐Bello, J., Ojeda, G. M., & Muñóz-Valle, J. F. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082893 · Cited by 5
Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections
Miyashita, N., Nakamori, Y., Ogata, M., Fukuda, N., Yamura, A., Ishiura, Y., & Ito, T. (2023) · Viruses · doi:10.3390/v15061300 · Cited by 5
Multimodal, broadly neutralizing antibodies against SARS-CoV-2 identified by high-throughput native pairing of BCRs from bulk B cells
Keitany, G. J., Rubin, B. E., Garrett, M. E., Musa, A., Tracy, J., Liang, Y., Ebert, P., Moore, A. J., Guan, J., Eggers, E. L., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.07.011 · Cited by 5
Antiviral Drugs and Vaccines for Omicron Variant: A Focused Review
Garg, N., Kunamneni, A. S., Garg, P., Sharma, S., Sharma, D., & Kunamneni, A. (2023) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2023/6695533 · Cited by 5
Structural basis for broad neutralization of human antibody against Omicron sublineages and evasion by XBB variant
Sun, H., Wang, Y., Chen, X., Jiang, Y., Wang, S., Huang, Y., Liu, L., Yu, L., Lan, M., Guo, H., et al. (2023) · Journal of Virology · doi:10.1128/jvi.01137-23 · Cited by 5
A potent neutralizing nanobody targeting a unique epitope on the receptor-binding domain of SARS-CoV-2 spike protein
Zhang, Y., Wang, D., Xiang, Q., Hu, X., Zhang, Y., Wu, L., Zhang, Z., Wang, Y., Zhao, J., McCormick, P. J., et al. (2023) · Virology · doi:10.1016/j.virol.2023.109925 · Cited by 5
Incidence and predictors of clinical failure after early treatment for mild‐to‐moderate COVID‐19 in high‐risk individuals: A multicentric cohort study
Mastrorosa, I., Cozzi‐Lepri, A., Borgo, C. D., Rosati, S., Rueca, M., Sarmati, L., Mastroianni, C. M., Fantoni, M., Maggi, F., Nicastri, E., et al. (2024) · Journal of Internal Medicine · doi:10.1111/joim.20030 · Cited by 5
Early Use of Sotrovimab in Children: A Case Report of an 11-Year-Old Kidney Transplant Recipient Infected with SARS-CoV-2
Chiara, C. D., Mengato, D., Pieri, M. D., Longo, G., Benetti, E., Venturini, F., Giaquinto, C., & Donà, D. (2022) · Children · doi:10.3390/children9040451 · Cited by 5
Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study
Manzano, G. S., Rice, D. R., Klawiter, E. C., Matiello, M., Gillani, R. L., Tauhid, S., Bakshi, R., & Mateen, F. J. (2022) · Multiple Sclerosis Journal · doi:10.1177/13524585221092309 · Cited by 5
Safety of convalescent plasma therapy for COVID-19 patients and analysis of viral kinetics: a single-center, open-label, single-arm, interventional study in Japan
Kutsuna, S., Saito, S., Takamatsu, Y., Terada, M., Togano, T., Kinoshita, N., Maeda, K., Matsunaga, A., Satake, M., Matsubayashi, K., et al. (2022) · GHM Open · doi:10.35772/ghmo.2022.01002 · Cited by 5
Implementation and Patient Outcomes of a Pediatric COVID-19 Monoclonal Antibody Program
Blind, J. E., Sapko, M. S., Killough, A., Thornton, H., & Watson, J. R. (2022) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piac107 · Cited by 5
Machine-Learning-Assisted Analysis of TCR Profiling Data Unveils Cross-Reactivity between SARS-CoV-2 and a Wide Spectrum of Pathogens and Other Diseases
Georgakilas, G. K., Galanopoulos, A. P., Tsinaris, Z., Kyritsi, M. A., Mouchtouri, V. Α., Speletas, M. G., & Hadjichristodoulou, C. S. (2022) · Biology · doi:10.3390/biology11101531 · Cited by 5
Treatment with Sotrovimab and Casirivimab/Imdevimab Enhances Serum SARS-CoV-2 S Antibody Levels in Patients Infected with the SARS-CoV-2 Delta, Omicron BA.1, and BA.5 Variants
Fujimoto, K., Mutsuo, S., Yasuda, Y., Arasawa, S., Tashima, N., Iwashima, D., & Takahashi, K. P. (2022) · Infectious Disease Reports · doi:10.3390/idr14060099 · Cited by 5
The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19
多賀谷, 悦., Kikuchi, K., Mitsuda, T., Ebihara, F., Maruyama, T., Hamada, Y., Kimura, T., Unagami, K., Kanzawa, T., Sekiguchi, H., et al. (2022) · Transplant Immunology · doi:10.1016/j.trim.2022.101777 · Cited by 5
Effects of the COVID-19 pandemic: new approaches for accelerated delivery of gene to first-in-human CMC data for recombinant proteins
Broly, H., Souquet, J., & Beck, A. (2023) · mAbs · doi:10.1080/19420862.2023.2220150 · Cited by 5
Pyronaridine tetraphosphate is an efficacious antiviral and anti-inflammatory active against multiple highly pathogenic coronaviruses
Ardanuy, J., Johnson, R. M., Dillen, C. A., Taylor, L. J., Hammond, H., Weston, S. M., & Frieman, M. B. (2023) · mBio · doi:10.1128/mbio.01587-23 · Cited by 5
Safety and efficacy of 5-aminolevulinic acid phosphate/iron in mild-to-moderate coronavirus disease 2019: A randomized exploratory phase II trial
Tanaka, T., Tashiro, M., Ota, K., Fujita, A., Sawai, T., Kadota, J., Fukuda, Y., Sumiyoshi, M., Ide, S., Tachikawa, N., et al. (2023) · Medicine · doi:10.1097/md.0000000000034858 · Cited by 5
Antiviral therapy of coronavirus disease 2019 (COVID-19)
Chen, P., Wang, J., & Chang, S. (2023) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2023.08.029 · Cited by 5
Real world effectiveness of sotrovimab in preventing COVID-19–related hospitalisation or death in patients infected with Omicron BA.2
Behzad, A. A., Mohamed, A., Ali, A., Niinuma, S. A., Butler, A. E., & AlQahtani, M. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.11.029 · Cited by 5
Impact of liver fibrosis on COVID-19 in-hospital mortality in Southern Italy
Galiero, R., Loffredo, G., Simeon, V., Caturano, A., Vetrano, E., Medicamento, G., Alfano, M., Beccia, D., Brin, C., Colantuoni, S., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0296495 · Cited by 5
Immune treatment in COVID-19
Menéndez, R., González, P., Latorre, A., & Méndez, R. (2022) · Revista Española de Quimioterapia · doi:10.37201/req/s01.14.2022 · Cited by 5
Estimated Impact of Oral Nirmatrelvir;Ritonavir on Reductions in Hospitalizations and Associated Costs within High-Risk COVID-19 Patients in the USPreprint
Sandin, R., Harrison, C., Draica, F., Wiemken, T. L., Ma, C., Fusco, M. D., Markson, L. E., & Dzingina, M. D. (2022) · Research Square · doi:10.21203/rs.3.rs-2191067/v1 · Cited by 5
90-Day outcomes in patients with severe COVID-19 pneumonia treated with invasive mechanical ventilation
Mineshita, M., Nishine, H., Handa, H., Inoue, T., Ishibashi, Y., Kawahata, K., Kunishima, H., Tsuchida, T., Takemura, H., Minoura, A., et al. (2024) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2024.09.018 · Cited by 4
Effectiveness of pharmacological treatments for COVID-19 due to SARS-CoV-2: a systematic literature review
García‐Vidal, C., González, J., Lumbreras, C., Salavert, M., Castro, A. A., Rubio-Rodríguez, D., & Rubio‐Terres, C. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1469681 · Cited by 4
Iguratimod, a promising therapeutic agent for COVID-19 that attenuates excessive inflammation in mouse models
Oba, S., Hosoya, T., Kawata, D., Komiya, Y., Iwai, H., Koike, R., Miyamoto, S., Kanno, T., Ainai, A., Suzuki, T., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177537 · Cited by 4
Coronavirus Disease 2019 (COVID-19) Vaccination Coverage and Effectiveness Among Pediatric Transplant Recipients
Cohen, E., Hinderstein, S. A., Carciofi, E., Hopkins, K., Kuzaro, H. A., & Yildirim, I. B. (2025) · Progress in Transplantation · doi:10.1177/15269248251383951 · Cited by 4
Omicron breakthrough infection in a kidney‐transplant patient given pre‐exposition casirivimab and imdevimab monoclonal antibodies
Kamar, N., Gouin, A., & Izopet, J. (2022) · Transplant Infectious Disease · doi:10.1111/tid.13803 · Cited by 4
A Single-center Experience in Treating Young Children at High Risk For Severe COVID-19 With Sotrovimab
Pruccoli, G., Bertorello, N., Funiciello, E., Mignone, F., Silvestro, E., Scolfaro, C., & Garazzino, S. (2022) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003552 · Cited by 4
Short-course remdesivir for healthcare-associated COVID-19: Case series from a non-acute care hospital
Takahashi, Y., Wakita, H., Ishihara, T., Okazaki, H., Ito, A., Iwata, M., Sonoda, S., & Doi, Y. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.08.025 · Cited by 4
Monoclonal Antibodies against SARS-CoV-2 Infection: Results from a Real-Life Study before the Omicron Surge
Scotto, R., Buonomo, A. R., Zumbo, G., Fusco, A. D., Esposito, N. D. P., Filippo, I. D., Nobile, M., Pinchera, B., Moriello, N. S., Villari, R., et al. (2022) · Vaccines · doi:10.3390/vaccines10111895 · Cited by 4
Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) position statement: COVID ‐19 management in patients with haemopoietic stem cell transplant and chimeric antigen receptor T cell
Perram, J., Purtill, D., Bajel, A. R., Butler, J., O'Brien, T. A., Teh, B. W., Gilroy, N. M., Ho, P. J., Doocey, R. T., Hills, T. E., et al. (2022) · Internal Medicine Journal · doi:10.1111/imj.15978 · Cited by 4
Safety of Pharmacotherapy in COVID-19 Patients: A Literature Review
Kryukov, А. V., Zhiryakova, A. S., Shevchuk, Y. V., Matveev, A. V., Vechorko, V. I., Валерьевич, А. О., Glagolev, S. V., Ильдарович, Т. И., Mirzaev, K. B., Денисенко, Н. П., et al. (2022) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2022-10-4-326-344 · Cited by 4
Prophylactic and early outpatient treatment of COVID-19 in patients with kidney disease: considerations from the Immunonephrology Working Group of the European Renal Association (ERA-IWG)
Hilhorst, M. L., Bemelman, F. J., Bruchfeld, A. N., Juarez, G. M. F., Floege, J., Frangou, E. A., Goumenos, D. S., van Kooten, C., Kronbichler, A., Stevens, K., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad044 · Cited by 4
Monoclonal Antibody Use for Coronavirus Disease 2019 in Pediatric Patients: A Multicenter Retrospective Study
Sherman, G., Lamb, G. S., Sharma, T. S., Lloyd, E. C., Nagel, J. L., Dandam, N. N., Oliveira, C. R., Sheikha, H., Anosike, B. I., Lee, P., et al. (2023) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piac124 · Cited by 4
A randomized phase 2 study on demeclocycline in patients with mild-to-moderate COVID-19
Iwahori, K., Nii, T., Yamaguchi, N., Kawasaki, T., Okamura, S., Hashimoto, K., Matsuki, T., Tsujino, K., Miki, K., Osa, A., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-41051-2 · Cited by 4
Remdesivir and SARS-CoV-2 monoclonal antibodies to prevent COVID-19 progression in hematological patients: an observational study
Vicente-Valor, J., Rodríguez, C., Ferris, M., Chamorro‐de‐Vega, E., Romero-Jiménez, R. M., Costas, D. G., BERMEJO, S. H., Tejerina, F., Osorio‐Prendes, S., Royuela, G. O., et al. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00519-8 · Cited by 4
Clinical trials of pharmacological interventions for SARS‐CoV‐2 published in leading medical journals report adherence but not how it was assessed
Lee, C., Otunla, A. A., Brennan, I., Aronson, J. K., & Nunan, D. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15992 · Cited by 4
A phase I/II study of adoptive SARS-CoV-2-specific T cells in immunocompromised hosts with or at risk of severe COVID-19 infection
Seng, M. S.-F., Ng, K. P., Soh, T. G., Tan, T. T., Chan, M., Maiwald, M., Tan, L. K., Linn, Y. C., & Leung, W. H. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.05.014 · Cited by 4
A Robust Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Specific T- and B-Cell Response Is Associated With Early Viral Clearance in SARS-CoV-2 Omicron-Infected Immunocompromised Individuals
Vergouwe, M., Biemond, J. J., van der Straten, K., van Pul, L., Kerster, G., Claireaux, M. A. F., Burger, J. A., van Dort, K. A., Kootstra, N. A., Jonges, M., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae306 · Cited by 4
Current development of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies (Review)
Zhang, T., Yang, D., Tang, L., & Hu, Y. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13272 · Cited by 5
Pooled analysis of the MANTICO2 and MONET randomized controlled trials comparing drug efficacy for early treatment of COVID-19 during Omicron waves
Mazzotta, V., Mazzaferri, F., Lanini, S., Mirandola, M., Cozzi‐Lepri, A., Vergori, A., Savoldi, A., Santoro, A., Maccarrone, G., Mastrorosa, I., et al. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106294 · Cited by 4
Ensitrelvir as a novel treatment option for mild-to-moderate COVID-19: a narrative literature review
Mukae, H., Yotsuyanagi, H., Ohmagari, N., Doi, Y., Yamato, M., Imamura, T., Sakaguchi, H., Sanaki, T., Sonoyama, T., Tsuge, Y., et al. (2025) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361251321724 · Cited by 4

Authors: Gupta, A., Gonzalez-Rojas, Y., Juarez, E., Crespo Casal, M., Moya, J., Falci, D. R., Sarkis, E., Solis, J., Zheng, H., Scott, N., Cathcart, A. L., Hebner, C. M., Sager, J., Mogalian, E., Tipple, C., Peppercorn, A., Alexander, E., Pang, P. S., Free, A., Brinson, C., Aldinger, M., & Shapiro, A. E.
Affiliations: William Osler Health System (CA)
From the Albion Finch Medical Centre, William Osler Health Centre, Toronto (A.G.); Optimus U (Y.G.-R.) and Florida International Medical Research (E.J.), Miami, Pines Care Research Center, Pembroke Pines (J.M.), and Sarkis Clinical Trials, Gainesville (E.S.) — all in Florida; Álvaro Cunqueiro Hospital, IIS Galicia Sur, Vigo, Spain (M.C.C.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (D.R.F.); Centex Studies, McAllen (J. Solis), and Central Texas Clinical Research, Austin (C.B.) — both in Texas; Vir Biotechnology, San Francisco (H.Z., A.L.C., C.M.H., J. Sager, E.M., E.A., P.S.P., M.A.); GlaxoSmithKline, Stevenage, United Kingdom (N.S., C.T.); GlaxoSmithKline, Cambridge, MA (A.P.); Pinnacle Research Group, Anniston, AL (A.F.); and the Departments of Global Health and Medicine, University of Washington, and Fred Hutchinson Cancer Research Center, Seattle (A.E.S.).
Hospital de Clínicas de Porto Alegre (BR)
The University of Texas at Austin (US)
VIR Biotechnology (United States) (US)
GlaxoSmithKline (United Kingdom) (GB)
GlaxoSmithKline (United States) (US)
University of Washington (US)
Corresponding author: Shapiro, Adrienne E.
ORCID: Pang, Phillip S.
Shapiro, Adrienne E.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2021-11-18
Volume: 385
Issue: 21
Pages: 1941-1950
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2107934
OpenAlex: W3208080692
Cited by: 1,086
References: 25
Citations by year: 2026: 25 · 2025: 72 · 2024: 119 · 2023: 294 · 2022: 509 · 2021: 62
FWCI: 78.13
Type: journal article
Language: en
Open access: green
doi.org
Licence: cc-by-nc-nd
www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
medRxiv (acceptedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Funders: Vir Biotechnology, Inc., in collaboration with GlaxoSmithKline
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
Keywords: sotrovimab, COVID-19 pandemic, SARS-CoV-2, neutralizing monoclonal antibodies, early treatment, disease progression, hospitalization, mortality, high-risk patients, non-hospitalized patients, presymptomatic treatment, adverse events
MeSH terms: SARS-CoV-2, COVID-19 Drug Treatment, Adult, Aged, Ambulatory Care, Double-Blind Method, Female, Hospitalization, Humans, Infusions, Intravenous, Length of Stay, Male, Middle Aged, Incidence, Disease Progression, Antibodies, Neutralizing, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks